^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD276 overexpression

i
Other names: CD276, CD276 Molecule, CD276 Antigen, B7 Homolog 3, B7-H3, B7RP-2
Entrez ID:
Related biomarkers:
2ms
Suppressive function of bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-187 in prostate cancer. (PubMed, Cancer Biol Ther)
Next, BMSC-exos carrying miR-187 contributed to repressed cell malignant features as well as limited tumorigenicity and tumor metastasis. Collectively, this study demonstrated that BMSC-derived exosomal miR-187 restrained prostate cancer by reducing CD276/JAK3-STAT3-Slug axis.
Journal
|
CD276 (CD276 Molecule) • JAK3 (Janus Kinase 3) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
CD276 overexpression • CD276 expression • CD2 overexpression
2ms
Anti-B7-H3 Antibody (T-1A5) Blocks Immunomodulatory Function of B7-H3 and Enhances NK and T Cell–Mediated Cytotoxicity against Breast Cancer Cells (SABCS 2022)
Our data suggests that B7-H3 is overexpressed in primary BC and inhibits immune-cell infiltration. Moreover, blocking the immunomodulatory functions of B7-H3 using anti-B7H3 antibody T-1A5 enhances NK and T cell–mediated killing of BC cells.
IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • CD4 (CD4 Molecule)
|
HER-2 expression • CD276 overexpression • CD276 expression
2ms
ATG-027, a first-in-class B7-H3/PD-L1 bispecific antibody, shows potent T cell activation capability and in vivo anti-tumor efficacy (SITC 2022)
ATG-027 can also inhibit the interaction between PD1/PD-L1 to rescue T cell activity suppression. ATG-027’s dual T cell activation function and powerful ADCC, CDC, and ADCP properties contribute to its promising anti-tumor efficacy in preclinical models.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • CD276 (CD276 Molecule) • IL2 (Interleukin 2)
|
PD-L1 expression • CD276 overexpression
|
ATG-027
2ms
B7-H3 is a Checkpoint Immunotherapy Target in Advanced Prostate Cancer Harboring PTEN and TP53 Defects (SITC 2022)
Cd276 deletion also reversed the immunosuppression characterized by increased tumor-infiltrating lymphocytes. Conclusions Our studies provide the genetic evidence for the tumor-promoting and immunosuppressive role of B7-H3 in prostate cancer and offer insights into combinatorial strategies for immunotherapy targeting B7-H3 in CRPC harboring PTEN and TP53 defects.
IO biomarker
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression • TP53 expression
2ms
AML-327 Novel Anti-B7-H3 Blocking Antibody Enhances NK Cell-Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice. (PubMed, Clin Lymphoma Myeloma Leuk)
Our data indicate that B7-H3 is overexpressed in AML and that an anti-B7-H3 antibody (T1-A5) not only blocks B7-H3's immunomodulatory function but also induces ADCC in AML cells in vitro and in vivo.
Preclinical • Journal
|
CD276 (CD276 Molecule) • CD34 (CD34 molecule)
|
CD276 overexpression • CD276 expression
3ms
Novel Anti–B7-H3 Blocking Antibody Enhances NK Cell–Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice (SOHO 2022)
Our data indicate that B7-H3 is overexpressed in AML and that an anti–B7-H3 antibody (T1-A5) not only blocks B7-H3’s immunomodulatory function but also induces ADCC in AML cells in vitro and in vivo.
Preclinical
|
CD276 (CD276 Molecule) • CD34 (CD34 molecule)
|
CD276 overexpression • CD276 expression
3ms
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. (PubMed, Eur Urol)
The frequent overexpression of B7-H3 in CRPC compared with normal tissue and other B7 family members implicates it as a highly relevant therapeutic target in these diseases. Mechanisms driving differences in B7-H3 expression across genomic subsets warrant investigation for understanding the role of B7-H3 in cancer growth and for the clinical development of B7-H3 targeted therapies.
Journal • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • AR (Androgen receptor) • CD276 (CD276 Molecule)
|
BRCA2 mutation • CD276 overexpression • CD276 expression • AR expression
|
ifinatamab deruxtecan (DS-7300)
4ms
B7-H3 immune checkpoint molecule in prostate cancer (ECP 2022)
B7-H3 protein is overexpressed in PCa making it a promising target for immunotherapies. Examining human tissue samples, we showed an association of B7-H3 expression and aggressive clinical features, including lymph node spread. In vitro experiments with acute and chronic loss of B7-H3 revealed an effect on migration and invasion.
IO biomarker
|
CD276 (CD276 Molecule) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
|
CD276 overexpression • CD276 expression
4ms
DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study (ESMO 2022)
Conclusions DS-7300 continues to demonstrate evidence of durable antitumor activity in heavily pretreated pts with SCLC, sqNSCLC, and mCRPC. These data support further clinical development of DS-7300, including a Ph 2 dose-optimization study in SCLC (NCT05280470) with starting dose levels of 8 mg/kg and 12.0 mg/kg.
P1/2 data
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
|
ifinatamab deruxtecan (DS-7300)
5ms
Investigation of multiple immune-checkpoints in the context of the disease for personalized therapy selection (EACR 2022)
Material and Methods Spatial biomarkers characterization on tumor tissues samples from resected NSCLC (adenocarcinoma and squamous cell carcinoma) tumors treated with adjuvant pembrolizumab therapy...Conclusion Multiplexed spatial high-throughput analysis allowed to investigate at the molecular level several actors involved in immune modulation pathways responsible of drug resistance. These findings highlighted the relevance of investigating multiple biomarkers to obtain a comprehensive strategy for personalized immune therapy selection.
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD44 • CD27 • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • GZMB (Granzyme B) • CD86 (CD86 Molecule)
|
CD276 overexpression • CD44 expression
|
Keytruda (pembrolizumab)
7ms
B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis. (PubMed, Breast Cancer Res Treat)
Taken together, B7-H3 can promote lung metastasis in breast cancer through activation of the Raf/MEK/ERK axis.
Journal
|
CD276 (CD276 Molecule) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2)
|
CD276 overexpression • CDH1 expression • VIM expression
|
PD98059
7ms
Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML. (PubMed, Blood)
Furthermore, treatment with ChT-1A5 in combination with human NK cells significantly prolonged survival in AML patient-derived xenograft models. Our results suggest that ChT-1A5 antibody can inhibit the immunosuppressive function of B7-H3 protein as well as induce ADCC in B7-H3+ AML.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
7ms
Clinical Significance of the Expression of Co-Stimulatory Molecule B7-H3 in Papillary Thyroid Carcinoma. (PubMed, Front Cell Dev Biol)
This is the first comprehensive study to elucidate the expression profile of B7-H3 in PTC. Our observations revealed that B7-H3 is a novel independent biomarker for predicting LNM and disease recurrence for PTC patients, and it thus may serve as an indicator that could be used to improve risk-adapted therapeutic strategies and a novel target for immunotherapy strategies for patients who undergo an aggressive disease course.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
8ms
LINC01123 promotes immune escape by sponging miR-214-3p to regulate B7-H3 in head and neck squamous-cell carcinoma. (PubMed, Cell Death Dis)
Notably, overexpression of LINC01123 or B7-H3 or downregulation of miR-214-3p inhibited the function of CD8T cells and promoted the progression of HNSCC. Therefore, LINC01123 acts as a miR-214-3p sponge to inhibit the activation of CD8T cells and promote the progression of HNSCC by upregulating B7-H3.
Journal
|
CD276 (CD276 Molecule) • MIR214 (MicroRNA 214)
|
CD276 overexpression
8ms
DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-based Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Activities in Preclinical Models. (PubMed, Mol Cancer Ther)
DS-7300a exerted potent antitumor activities against B7-H3-expressing tumors in in vitro and in vivo models including PDX mouse models and showed acceptable pharmacokinetic and safety profiles in nonclinical species. Therefore, DS-7300a may be effective in treating patients with B7-H3-expressing solid tumors in a clinical setting.
Preclinical • Journal • PARP Biomarker
|
CHEK1 (Checkpoint kinase 1)
|
CD276 overexpression • CD276 expression
|
ifinatamab deruxtecan (DS-7300)
9ms
Tumor-targeting and efficacy of B7H3/GD2 bispecific SNIPER antibodies (AACR 2022)
The Fab arms of SNIPER targeting GD2 and B7H3 each have low-to-moderate affinity. SNIPER binds with strong avidity when both arms bind to their antigens on the same cell. Stronger avidity through both arms binding results in high-tumor specificity.
Clinical
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
|
Unituxin (dinutuximab)
9ms
A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity. (PubMed, Life (Basel))
This bispecific antibody also demonstrated potent antitumor activity in humanized mice xenograft models. These results revealed that the novel anti-B7-H3 × anti-CD3 bispecific antibody has the potential to be employed in treatment of B7-H3-positive solid tumors.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression
10ms
GOLM1 as a Potential Therapeutic Target Modulates B7-H3 Secretion to Drive Ovarian Cancer Metastasis. (PubMed, Evid Based Complement Alternat Med)
Both GOLM1 and B7-H3 knockdown restrained tumor growth and metastasis in immunodeficient mice and prolonged the survival rate. GOLM1 acts as an initial oncogenic driving gene by promoting ovarian cancer invasion and metastasis through modulating B7-H3 protein maturation and secretion.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression
10ms
CD276 (B7H3) improve cancer stem cells formation in cervical carcinoma cell lines. (PubMed, Transl Cancer Res)
The relationship between CD276 and chemotherapy resistance of HeLa cell were evaluated by cisplatin treatment...Furthermore, we verify the CD276's function on HeLa xenotransplantation mice model. These results suggest that CD276 elevates the self-renewal capacity of HeLa CSCs.
Preclinical • Journal
|
CD276 (CD276 Molecule) • SOX2 • POU5F1 (POU Class 5 Homeobox 1)
|
CD276 overexpression • CD276 expression
|
cisplatin
11ms
Preliminary study on the effect of B7H3 interaction with fibronectin on apoptosis of human chronic myeloid leukemia cells (PubMed, Zhonghua Xue Ye Xue Za Zhi)
There is an interaction between B7H3 and FN (P=0.036) , and this interaction promoted cell adhesion (P<0.05) , inhibited cell apoptosis (P<0.05) , and activated the PI3K/AKT signaling pathway (P<0.05) . B7H3 interacts with FN to promote cell adhesion and may inhibit K562 cell apoptosis by activating the PI3K/AKT signaling pathway.
Journal
|
CD276 (CD276 Molecule) • FN1 (Fibronectin 1)
|
CD276 overexpression
11ms
DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A subgroup analysis of a phase 1/2 multicenter study. (ASCO-GU 2022)
DS-7300 was well tolerated with an acceptable safety profile in pts with mCRPC. The preliminary safety and efficacy data are encouraging and warrant further investigation.
Clinical • P1/2 data
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
|
ifinatamab deruxtecan (DS-7300)
12ms
Overexpression of B7-H3 Is Associated With Poor Prognosis in Laryngeal Cancer. (PubMed, Front Oncol)
These results show that B7-H3 is upregulated in LSCC. Therefore, B7-H3 may serve as a biomarker of poor prognosis and a promising therapeutic target in LSCC.
Journal
|
CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule)
|
CD276 overexpression • CD8 expression
1year
Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy. (PubMed, Genes (Basel))
The expression of CD276 showed a weak but statistically significant positive correlation with tumor diameter, but we did not find a significant association between CD276 expression and other histopathological clinical factors, or the response to initial therapy. A search of published data identified the monoclonal antibody (inhibitor) enoblituzumab as a potential drug for patients diagnosed with MTC overexpressing CD276.
Journal • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression • CD2 overexpression
|
enoblituzumab (MGA271)
over1year
[VIRTUAL] A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors (ESMO 2021)
DS-7300 was generally well tolerated with early signs of clinical activity, including objective responses, in pts with pretreated advanced solid tumors. Expansion cohorts are currently enrolling to evaluate DS-7300 in selected tumor types.
Clinical • P1/2 data
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
|
ifinatamab deruxtecan (DS-7300)
over1year
Adrenocortical Carcinoma Steroid Profiles: In Silico Pan-Cancer Analysis of TCGA Data Uncovers Immunotherapy Targets for Potential Improved Outcomes. (PubMed, Front Endocrinol (Lausanne))
Treatments to reduce immune evasion, as well as the use of other natural and pharmacological immune activators, should include prior pharmacological inhibition of steroidogenesis. Attempts to combine these with tumor cell proliferation inhibitors, if they do not affect cells of the immune system, may produce interesting results.
Journal • PD(L)-1 Biomarker • IO biomarker • Pan tumor
|
CD276 (CD276 Molecule) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
CD276 overexpression • CD2 overexpression
over1year
MicroRNA miR-29a Inhibits Colon Cancer Progression by Downregulating B7-H3 Expression: Potential Molecular Targets for Colon Cancer Therapy. (PubMed, Mol Biotechnol)
In animal models, upregulation of miR-29a slowed down the growth of subcutaneous xenotransplanted tumors and resulted in prolonged survival time. MiR-29a downregulates B7-H3 expression and accordingly inhibits colon cancer progression, invasion, and migration, indicating miR-29a and B7-H3 might represent novel molecular targets for advanced immunotherapy in colon cancer.
Journal • IO biomarker
|
CD276 (CD276 Molecule) • MIR29A (MicroRNA 29a)
|
CD276 overexpression • CD276 expression
over1year
The Inhibition of B7H3 by 2-HG Accumulation Is Associated With Downregulation of VEGFA in IDH Mutated Gliomas. (PubMed, Front Cell Dev Biol)
Inhibition of autophagy by inhibitors like leupeptin, chloroquine (CQ), and Bafilomycin A1 (Baf-A1) blocks the degradation of B7H3 in glioma cells...B7H3 and VEGFA are decreased in IDH-mutated gliomas and further reduced in 2-HG gliomas compared to 2-HG glioma sections by IHC staining. Our study demonstrates that B7H3 is preferentially overexpressed in IDH wild-type gliomas and could serve as a potential theranostic target for the precise treatment of glioma patients with wild-type IDH.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CD276 (CD276 Molecule) • MMP2 (Matrix metallopeptidase 2)
|
CD276 overexpression • IDH1 R132H • CD276 expression
|
chloroquine phosphate
over1year
B7-H3 suppresses doxorubicin-induced senescence-like growth arrest in colorectal cancer through the AKT/TM4SF1/SIRT1 pathway. (PubMed, Cell Death Dis)
More importantly, B7-H3 inhibited DOX-induced cellular senescence of CRC cells in vivo. Therefore, targeting B7-H3 or the B7-H3/AKT/TM4SF1/SIRT1 pathway might be a new strategy for promoting cellular senescence-like growth arrest during drug treatment in CRC.
Journal
|
CD276 (CD276 Molecule) • IFIT3 (Interferon Induced Protein With Tetratricopeptide Repeats 3) • TM4SF1 (Transmembrane 4 L Six Family Member 1)
|
CD276 overexpression
|
doxorubicin hydrochloride
over1year
[VIRTUAL] Preclinical Evaluation of B7-H3-Targeted CAR-T Cells against Triple Negative Breast Cancer (ASGCT 2021)
B7-H3 is overexpressed in several TNBC cell lines and B7-H3-targeted CAR-T cells preferentially attack tumor cells with high B7-H3 expression. This B7-H3-targeted CAR-T therapy may provide an alternative approach for TNBC patients who have few therapeutic options.
Preclinical • CAR T-Cell Therapy • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD276 (CD276 Molecule) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CD86 (CD86 Molecule)
|
TMB-H • CD276 overexpression • CD276 expression
over1year
Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma. (PubMed, BMC Urol)
CD276 expression is significantly elevated in urothelial carcinoma cells in all stages but varies between individuals considerably. Reduced CD276 expression in normal urothelial cells may imply that these cells would be protected from CD276-mediated immuno therapies.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
over1year
B7-H3, Negatively Regulated by miR-128, Promotes Colorectal Cancer Cell Proliferation and Migration. (PubMed, Cell Biochem Biophys)
B7-H3 expression is upregulated in CRC tissues and cell lines, and B7-H3 participates in promoting the proliferation and migration of CRC cells. Besides, B7-H3 expression is negatively regulated by miR-128 in CRC.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression • miR-128 expression
over1year
[VIRTUAL] Novel human B7-H3 knock-in mice demonstrate efficacy of anti-B7-H3 immunotherapy in vivo (AACR 2021)
Taken together, B7-H3 humanized mice are a useful tool for in vivo efficacy evaluation and selection of candidate human B7-H3 antibodies for advancement to clinical trials. In addition, Biocytogen has generated B7-H3/PD-1 and B7-H3/PD-1/PD-L1 multi-gene humanized mice to evaluate B7-H3/PD-1/PD-L1 combination therapies in vivo.
Preclinical
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
over1year
CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma. (PubMed, J Gastrointest Oncol)
Overexpression of CD276 promoted glucose metabolism in tumor and inhibited the function of CD8+ T cells. Therefore, strategies targeting CD276 might improve the response to cancer immunotherapy of ESCC patients.
Journal • CAR T-Cell Therapy • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule)
|
CD276 overexpression • CD2 overexpression
over1year
[VIRTUAL] Targeting B7-H3 in squamous cell carcinoma of the head and neck: Preclinical proof-of-concept with the investigational anti-B7-H3 antibody-drug conjugate, MGC018 (AACR 2021)
We are developing therapeutics targeting B7-H3, including enoblituzumab, an Fc-engineered anti-B7-H3 monoclonal antibody, and MGC018, a duocarmycin-based B7-H3 ADC, both of which are currently being evaluated in clinical studies. B7-H3 is frequently overexpressed in SCCHN. At clinically relevant dose levels, MGC018 demonstrated potent antitumor activity in vivo toward SCCHN CDX mouse models and the majority of SCCHN PDX mouse models examined. These results support SCCHN as a potential indication that may be responsive to ADC-based treatments directed toward B7-H3.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
|
vobramitamab duocarmazine (MGC018) • enoblituzumab (MGA271)
over1year
[VIRTUAL] B7-H3 as a therapeutic target in prostate cancer (AACR 2021)
mB7-H3 is highly expressed in advanced PC, with higher expression associating with BRCA2 and ATM loss of function alterations and low intratumor TILs. B7-H3 may be an actionable target for treating this disease subset.
Late-breaking abstract • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
|
BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ATM (ATM serine/threonine kinase) • CD276 (CD276 Molecule)
|
BRCA2 mutation • ATM mutation • CD276 overexpression • CD276 expression • ATM expression
almost2years
The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models. (PubMed, Clin Cancer Res)
m276-SL-PBD has significant anti-tumor activity across a broad panel of pediatric solid tumor PDX models.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
almost2years
B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression. (PubMed, Cell Death Dis)
Moreover, we verified that B7-H3 upregulated VEGFA expression and angiogenesis by activating the NF-κB pathway. Collectively, our findings identify the B7-H3/NF-κB/VEGFA axis in promoting CRC angiogenesis, which serves as a promising approach for CRC treatment.
Journal
|
CD276 (CD276 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1)
|
CD276 overexpression • VEGFA expression